

## 7. Literaturverzeichnis

1. AbdAlla S, Lothar H, Abdel-Tawab AM, Quitterer U. The Angiotensin II AT<sub>2</sub> Receptor is an AT<sub>1</sub> Receptor Antagonist. *J Biol Chem.* 2001; p 39721-39726.
2. Agha A, Schluter H, König S, Biel K, Tepel M, Zidek W. A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. *J Vasc Res.* 1992; 29(3):281-9.
3. Barton M: Herz und Gefäße. In Abdolvahab-Emminger H (ed): „Exaplan“. München, 1999.
4. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. *Curr Atheroscler Rep.* 2003; 5(6):492-9.
5. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. *Biochem J.* 1997; 325(Pt 2):449-54.
6. Berk BC. Angiotensin type 2 receptor (AT<sub>2</sub>R): a challenging twin. *Sci STKE.* 2003; (181):PE16.
7. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. *Am J Physiol Heart Circ Physiol.* 2001; 281:H2337-H2365.
8. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood pressure changes produced by kidney cross transplantation between spontaneously hypertensive rats and normotensive rats. *Clin Sci Mol Med.* 1974; 47(5):435-448.
9. Bienvenut WV, Deon C, Pasquarello C, Campbell JM, Sanchez J-C, Vestal ML, Hochstrasser DF. Matrix-assisted laser desorption/ionisation-tandem mass spectrometry with high resolution and sensitivity for identification and characterisation of proteins. *Proteomics.* 2002; No 2:pp868-876.
10. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. *Am J Med Sci.* 2003; 326(1):15-24.
11. Bühling KJ, Lepenies J, Witt K. Intensivkurs: Allgemeine und spezielle Pathologie. München, 2000.
12. Burgis E. Allgemeine und spezielle Pharmakologie. München, 2000.

13. Burnier M, Brunner HR. Die Angiotensin-II-Antagonisten in der heutigen Praxis. *Cardiovasc.* 2002; No 2.
14. Burnier M. Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension. *Drugs.* 2002; 62 Spec No 1:21-9.
15. Burnier M. Angiotensin II type 1 receptor blockers. *Circulation.* 2001; 103(6):904-12.
16. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. *Blood Press.* 2001; 10 Suppl 1:6-11.
17. Cairns V, Keil U, Doering A, Koenig W, Stieber J, Kleinbaum DG. Oral contraceptive use and blood pressure in a German metropolitan population. *Int J Epidemiol.* 1985; 14(3):389-95.
18. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. *Int J Biochem Cell Biol.* 2003; 35(6):784-91.
19. Campbell DJ, Bouhnik J, Menard J, Corcol P. Identity of angiotensinogen precursors of rat brain and liver. *Nature.* 1984; 308(5955):206-8.
20. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. *J. Clin. Invest.* 1986; 78(1):31-9.
21. Carretero OA, Oparil S. Essential hypertension : part II: treatment. *Circulation.* 2000; 101(4):446-53.
22. Chansel D, Ardaillou R. Active metabolites derived from angiotensin II. *Nephrologie.* 1998; 19(7):427-32.
23. Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin-(1-7) metabolism in the kidney. *Nephrol Dial Transplant.* 2001; 16 Suppl 1:22-6.
24. Csikos T, Chung O, Unger T. Receptors and their classification: focus on angiotensin II and the AT2 receptor. *J Hum Hypertens.* 1998; 12(5):311-8.
25. Dahl LK, Knudsen KD, Iwai J. Humoral transmission of hypertension: evidence from parabiosis. *Circ Res.* 1969; 24(5 Suppl):21-33.
26. de Gasparo M. AT (1) and AT (2) angiotensin II receptors: key features. *Drugs.* 2002; 62 Spec No 1:1-10.
27. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev.* 2000; 52(3):415-72.

28. DiBona GF. The sympathetic nervous system and Hypertension. *Hypertension*. 2004; 43(2):147-150.
29. Dietze GJ, van Erckelens F, Bunse M, Jung WI. Pathogenesis of coronary disease. *Z Kardiol*. 2000; 89 Suppl 7:7-10.
30. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. *Clin Sci*. 2001; 100(5):481-92.
31. Dzau VJ, Re RN. Evidence for the existence of renin in the heart. *Circulation*. 1987; 75 (1Pt2), I 134-6.
32. Epidemiologie der Hypertonie, Deutsche Liga zur Bekämpfung des hohen Blutdruckes. 1998.
33. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. *N Engl J Med*. 1987; 317(6):350-7.
34. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function and natriuresis. *J Am Soc Nephrol*. 1998; 9(9):1716-22.
35. Gallinat S, Busche S, Raizada MK, Sumners C. The angiotensin II type 2 receptor: an enigma with multiple variations. *Am J Physiol Endocrinol Metab*. 2000; 278(3):E357-74.
36. Ganten D, Lang RE, Lehmann E, Unger T. Brain angiotensin: on the way to becoming a well studied neuropeptide system. *Biochem Pharmacol*. 1984; 33(22):3523-8.
37. Gasse C, Hense HW, Stieber J. Assessing hypertension management in the community: trends of prevalence, detection, treatment and control of hypertension in the MONICA Project, Augsburg 1984-1995. *J Hum Hypertens*. 2001; 15:27-36.
38. Girndt J, Scheler F. Clinical course and pathogenesis of oral contraceptive hypertension. *Med Klein*. 1977; 72(41):1680-4.
39. Gluzman Y. SV 40-transformed simian cells support the replication of early SV 40 mutants. *Cell*. 1981; 23,175-182.
40. Gohlke P, Pees C, Unger T. AT 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension*. 1998; 31(1Pt 2):349-55.
41. Gonzalez RP, Falimirski ME. The role of angiography in periclavicular penetrating trauma. *Am Surg*. 1999; 65(8):711-3.

42. Graham, FL, Smiley J, Russel WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol.* 1977; 36,59-72.
43. Gross R, Schölmerich P, Gerok W. *Die Innere Medizin.* Stuttgart, 1996.
44. Haskell WL. Cardiovascular disease prevention and lifestyle interventions: effectiveness and efficacy. *J Cardiovasc Nurs.* 2003; 18(4):245-55.
45. Helin K, Stoll M, Meffert S, Stroth U, Unger T. The role of angiotensin receptors in cardiovascular diseases. *Ann Med.* 1997; 29(1):23-9.
46. Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT (2) subtype receptor of angiotensin II: from large arteries to the microcirculation. *Hypertension.* 2001; 38(5):1150-7.
47. Herold G. *Innere Medizin.* Köln, 2001.
48. Hillenkamp F, Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. *Methods Enzymol.* 1990; 193: 280-95.
49. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen J Y, Dzau V J. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. *Circ Res.* 1999; 84(8):876-82.
50. Inagami T, Kambayashi Y, Ichiki T, Tsuzuki S, Eguchi S, Yamakawa T. Angiotensin receptors: molecular biology and signalling. *Clin Exp Pharmacol Physiol.* 1999; 26(7):544-9.
51. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Jensen G, Friberg P. Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension. *Hypertension.* 2000; 36(4):543-8.
52. Karow T, Lang R. *Pharmakologie und Toxikologie.* Köln, 1998.
53. Kaufmann R, Kirsch D, Sprengler B. Sequencing of peptides in a time-of-flight mass spectrometer: evaluation of postsource decay following matrix-assisted laser desorption ionisation (MALDI). *Int J Mass Spectrom Ion Proc.* 1994; 131:355-385.
54. Küttler T. *Kurzlehrbuch Allgemeine Pharmakologie und Toxikologie.* München, 2002.
55. Kusserow H, Unger T. Vasoactive peptides, their receptors and drug development. *Basic Clin Pharmacol Toxicol.* 2004; 94(1):5-12.
56. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. *Hypertension.* 1992; 19(1 Suppl):I61-6.

57. Landsberg L. Obesity and hypertension: experimental data. *J Hypertens Suppl.* 1992; 10(7):S195-201.
58. Law M. Salt, blood pressure and cardiovascular disease. *J Cardiovasc Risk.* 2000; 7:5-8.
59. Lees KR, MacFadyen RJ, Doig JK, Reid JL. Role of angiotensin in the extravascular system. *J Hum Hypertens.* 1993; 7 Suppl 2:S7-12.
60. Löffler G, Petrides P. *Physiologische Chemie.* Berlin, 1990.
61. Löffler G. *Basiswissen Biochemie mit Pathobiochemie.* Berlin, 1999.
62. Lüllmann H, Mohr K, Ziegler A. *Taschenatlas der Pharmakologie.* Stuttgart, 1994.
63. Mazza CB, Cavanaugh JY, Neue UD, Phillips DJ. Role of mass spectrometry in the purification of peptides and proteins. *J of Chromatography B,* 2003; p 91-97.
64. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. *Hypertension.* 2001; 38(3 Pt 2):635-8.
65. Mizuno K. Renin in adrenal: an overview of its synthesis, subcellular localization and functions. *J Med Sci.* 1991; 37(2):41-57
66. Nchinda TC. Research capacity development for CVD prevention: the role of partnerships. *Ethn Dis.* 2003; 13(2 Suppl 2):S40-4.
67. Osterhues HH, Hombach V: Hypertonie/Hypotonie. In Pfreundschuh M, Schölmerich J (eds): „Pathophysiologie Pathobiochemie“. München, 2000.
68. Persson M, Carlberg B, Mjorndal T, Asplund K, Bohlin J, Lindholm L. 1999 WHO/ISH Guidelines applied to a 1999 MONICA sample from northern Sweden. *J Hypertens.* 2002; 20(1):29-35.
69. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. *Regul Pept.* 1993; 43 (1-2):1-20.
70. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restriction on blood pressure and serum lipids in overweight men. *Hypertension.* 1992; 20(4):533-41.
71. Rahn KH, Barenbrock M, Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. *J Hypertens.* 1999; 17:11-14.
72. Regitz-Zagrosek V, Neuss M, Holzmeister J, Warnecke C, Fleck E. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. *J Mol Med.* 1996; 74(5):233-51.

73. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. *Hypertension*. 2002; 39(3):799-802.
74. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. *Hypertension*. 2001; 38(6):1382-7.
75. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. *Cardiovasc Pharmacol*. 1992; 19 Suppl 6: 80-8
76. Schluter H, Kluth B, Borjesson-Stoll R, Nordhoff E, Zidek W. Partial purification and characterization of a circulating hypertensive factor in spontaneously hypertensive rats. *Eur J Biochem*. 1993; 218(1):67-73.
77. Schluter H, Grobeta I, Bachmann J, Kaufmann R, van der Giet M, Tepel M, Nofer JR, Assmann G, Karas I, Jankowski J, Zidek W. Diadenosine phosphates and the physiological control of blood pressure. *Nature*. 1994; 367, 186.
78. Schratzenholz A. Methoden der Proteomforschung. Molekulare Analyse der Proteinexpression. Berlin, 2001.
79. Sigma-Aldrich Co. Biochemikalien und Reagenzien für die Life Science Forschung. Taufkirchen, 2002.
80. Silbernagl S, Despopoulos A. Taschenatlas der Physiologie. Stuttgart, 1991.
81. Silbernagl S, Lang F. Taschenatlas der Pathophysiologie. Stuttgart, 1998.
82. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med*. 1993;153(5):598-615.
83. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*. 1993; 16(2):434-44.
84. Suzuki J, Horiuchi M. Renin-angiotensin system and heart failure. *Nippon Rinsho*. 2003; 61(5):751-5.
85. Suzuki Y, Ruiz-Ortega M, Egido J. Angiotensin II: a double-edged sword in inflammation. *J Nephrol*. 2000; 13 Suppl 3:S101-10.
86. Tepel M, Schlotmann R, Barenbrock M, Kisters K, Klaus T, Spieker C, Walter M, Meyer C, Bretzel RG, Zidek W. Lymphocytic Na<sup>+</sup>-H<sup>+</sup> exchange increases after an oral glucose challenge. *Circ Res*. 1995; 77(5):1024-9.

87. Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. *Hypertens Res.* 1999; 22(2):147-53.
88. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J Clin Invest.* 1999; 104(7):925-35.
89. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. *Hypertension.* 1996; 28(5):916-8.
90. Unger T. Blood pressure lowering and renin-angiotensin system blockade. *J Hypertens.* 2003 Jul;21 Suppl 6:S3-7.
91. Unger T, Badoer E, Ganten D, Lang RE, Rettig R. Brain angiotensin: pathways and pharmacology. *Circulation.* 1988; 77(6Pt2):I-40-54
92. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. *J Hypertens Suppl.* 1998; 16(7):S3-9.
93. Urata H, Tanabe Y, Kiyonaga A, Ikeda M, Tanaka H, Shindo M, Arakawa K. Antihypertensive and volume-depleting effects of mild exercise on essential hypertension. *Hypertension.* 1987; 9(3):245-52.
94. Van der Giet M, Khattab M, Borgel J, Schlüter H, Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol.* 1997; 120(8):1453-60.
95. Wall DB, Berger SJ, Finch JW, Cohen SA, Richardson K, Chapman R, Drabble D, Brown J, Gostick D. Continuous sample deposition from reversed-phase liquid chromatography to tracks on a matrix-assisted laser desorption/ionization precoated target for the analysis of protein digests. *Electrophoresis.* 2002; 23(18):3193-204.
96. Weinstock JV, Kassab JT. Angiotensin II stimulation of granuloma macrophage phagocytosis and actin polymerization in murine schistosomiasis mansoni. *Cell Immunol.* 1984; 89(1):46-54.
97. Weinstock JV, Blum AM. Granuloma macrophages in murine schistosomiasis mansoni generate components of the angiotensin system. *Cell Immunol.* 1984; 89(1):39-45.
98. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. *J Hypertens.* 1999; 17:151-183.

99. Wright GL, McCumbee WD. A hypertensive substance found in the blood of spontaneously hypertensive rats. *Life Sci.* 1984; 34(16):1521-8.
100. Yin G, Yan C, Berk BC. Angiotensin II signaling pathways mediated by tyrosine kinases. *Int J Biochem Cell Biol.* 2003; 35(6):780-3.
101. Zidek W, Sachinidis A, Heckmann U, Storkebaum W, Schmidt W, Vetter H. Humoral factors in primary hypertension. *J Clin Hypertens.* 1985; 1(3):257-64.
102. Zidek W, Heckmann U, Losse H, Vetter H. Effects on blood pressure of cross circulation between spontaneously hypertensive and normotensive rats. *Clin Exp Hypertens A.* 1986; 8(3):347-54.